Rebiotix and Ferring announce world’s first with positive preliminary pivotal Phase 3 data for investigational microbiome-based therapy RBX2660

Rebiotix and Ferring are the first to announce positive preliminary results on primary efficacy endpoint from ongoing pivotal Phase 3 clinical trial for RBX2660 RBX2660 is an investigational, non-antibiotic, microbiome-based therapy, developed to reduce Clostridiodes difficile (C. diff) infection recurrences CDC defines C. diff as a major burden to patients and doctors and an urgent […]

Rebiotix, a Ferring Company, Completes Enrollment for First-Ever, Pivotal Phase 3 Clinical Trial of Microbiota-based RBX2660

Enrollment completion for the first Phase 3 clinical trial in microbiome industry Largest randomized, double-blinded study, with over 300 patients enrolled aimed to demonstrate the potential benefit of RBX2660 in reducing rates of recurrent Clostridioides difficile (C. diff) infection Rebiotix intends to use the results from the Phase 3 trial to serve as the basis […]

Angel Tax Credit Program Reopens; Medical Alley Applauds Minnesota’s Return to an Early-Stage Growth Agenda

Minneapolis, MN – Medical Alley Association is thrilled to announce that starting July 1, 2019 the Minnesota Department of Employment and Economic Development (DEED) will be accepting applications for the newly-reenacted Angel Tax Credit Program. Medical Alley Association thanks Senator Paul T. Anderson and Representative Carlie Kotyza-Witthuhn for authoring this bill, as well as Governor […]